Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GSK plc stock logo
GSK
GSK
$37.82
-2.4%
$37.41
$31.72
$45.93
$78.28B0.584.47 million shs5.29 million shs
Takeda Pharmaceutical Company Limited stock logo
TAK
Takeda Pharmaceutical
$14.91
+0.2%
$14.23
$12.58
$15.31
$47.43B0.461.80 million shs1.37 million shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GSK plc stock logo
GSK
GSK
-2.55%-2.14%+0.62%+11.83%-10.83%
Takeda Pharmaceutical Company Limited stock logo
TAK
Takeda Pharmaceutical
+0.20%-0.96%+3.51%+12.58%+9.03%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
GSK plc stock logo
GSK
GSK
2.8278 of 5 stars
2.35.02.50.02.90.01.3
Takeda Pharmaceutical Company Limited stock logo
TAK
Takeda Pharmaceutical
2.2265 of 5 stars
0.03.02.50.01.90.02.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GSK plc stock logo
GSK
GSK
2.60
Moderate Buy$43.2514.35% Upside
Takeda Pharmaceutical Company Limited stock logo
TAK
Takeda Pharmaceutical
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest TAK and GSK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
2/12/2025
GSK plc stock logo
GSK
GSK
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageEqual Weight
(Data available from 4/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GSK plc stock logo
GSK
GSK
$31.38B2.49$5.98 per share6.32$8.07 per share4.69
Takeda Pharmaceutical Company Limited stock logo
TAK
Takeda Pharmaceutical
$4.58T0.01$3.49 per share4.27$15.39 per share0.97
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GSK plc stock logo
GSK
GSK
$3.29B$1.5923.798.131.128.13%48.59%11.11%4/30/2025 (Estimated)
Takeda Pharmaceutical Company Limited stock logo
TAK
Takeda Pharmaceutical
$994.06M$0.4037.269.030.244.53%9.39%4.53%5/8/2025 (Estimated)

Latest TAK and GSK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/30/2025N/A
GSK plc stock logo
GSK
GSK
$1.06N/AN/AN/A$7.52 billionN/A
2/5/2025Q4 2024
GSK plc stock logo
GSK
GSK
$0.44$0.59+$0.15$0.26$7.75 billionN/A
1/30/2025Q3 2025
Takeda Pharmaceutical Company Limited stock logo
TAK
Takeda Pharmaceutical
$0.34$0.42+$0.08$0.05N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
GSK plc stock logo
GSK
GSK
$1.574.15%-17.33%98.74%N/A
Takeda Pharmaceutical Company Limited stock logo
TAK
Takeda Pharmaceutical
$0.533.56%-8.36%132.50%N/A

Latest TAK and GSK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/5/2025
GSK plc stock logo
GSK
GSK
quarterly$0.39324.2%2/21/20252/21/20254/10/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GSK plc stock logo
GSK
GSK
1.12
0.78
0.52
Takeda Pharmaceutical Company Limited stock logo
TAK
Takeda Pharmaceutical
0.63
1.31
0.72

Institutional Ownership

CompanyInstitutional Ownership
GSK plc stock logo
GSK
GSK
15.74%
Takeda Pharmaceutical Company Limited stock logo
TAK
Takeda Pharmaceutical
9.17%

Insider Ownership

CompanyInsider Ownership
GSK plc stock logo
GSK
GSK
10.00%
Takeda Pharmaceutical Company Limited stock logo
TAK
Takeda Pharmaceutical
0.04%
CompanyEmployeesShares OutstandingFree FloatOptionable
GSK plc stock logo
GSK
GSK
90,1002.07 billion1.87 billionOptionable
Takeda Pharmaceutical Company Limited stock logo
TAK
Takeda Pharmaceutical
47,3003.18 billion3.18 billionOptionable

Recent News About These Companies

Takeda dedicated to advanced healthcare
Takeda reaffirms patient-centric mission in Vietnam: GM

New MarketBeat Followers Over Time

Media Sentiment Over Time

GSK stock logo

GSK NYSE:GSK

$37.82 -0.92 (-2.37%)
Closing price 04/1/2025 03:59 PM Eastern
Extended Trading
$37.98 +0.16 (+0.42%)
As of 04/1/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Takeda Pharmaceutical stock logo

Takeda Pharmaceutical NYSE:TAK

$14.90 +0.04 (+0.24%)
Closing price 04/1/2025 03:58 PM Eastern
Extended Trading
$14.94 +0.03 (+0.20%)
As of 04/1/2025 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.